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ABSTRACT
Background: Weight gain is a common side effect of many
therapies for type 2 diabetes (T2DM). Selecting utility values
for incorporation into cost-utility analyses (CUAs) of T2DM
therapies is difﬁcult because of variations in methodologies to
elicit utilities and other study limitations.
Methods: A review of the medical literature was conducted
to identify studies assessing the impact of body weight on
patient utility.
Results: Eighteen articles presented either: 1) utility values
by body-mass index (BMI) or body weight, or 2) the change
in utility scores or quality-adjusted life-years based on unit
changes in BMI or body weight. Regardless of the study
population or methodology used to elicit utility scores, all
studies reviewed found that as body weight increased, patient
utility decreased. Utility scores obtained using standard
gamble were generally higher than those using time trade-off
(TTO) or the EQ-5D. Most studies reported utility scores
stratiﬁed by BMI and used regression analyses to attribute the
difference in utility scores to differences in weight while con-
trolling for other factors. Studies generally assumed a con-
stant change in utility occurs with a one unit change in BMI.
Recent studies, however, demonstrate the magnitude of
changes in utility may vary depending on 1) valuing weight
loss versus weight gain; 2) valuing a small or large change in
body weight; and 3) baseline BMI.
Conclusions: Various utility values associated with body
weight using different methodologies have been published.
Careful consideration should be given to determine the most
appropriate utility values to use in CUAs of T2DM therapies.
Keywords: body-mass index, body weight, type 2 diabetes,
utility.
Introduction
Obesity has reached epidemic proportions worldwide
as more than 1 billion adults are overweight with at
least 300 million adults identiﬁed as obese [1]. An
adult classiﬁed as overweight has a body-mass index
(BMI) between 25.0 and 29.9 kg/m2, while an indi-
vidual who is obese has a BMI of at least 30 kg/m2 [2].
It is well established that the prevalence of many
conditions such as type 2 diabetes mellitus (T2DM),
high blood pressure, dyslipidemia, and cardiovascular
disease increases with an increase in body weight
[2–4]. In addition, being overweight or obese contrib-
utes to decreases in life expectancy [5,6] and leads to
decreases in health-related quality of life (HRQOL)
[7–9].
Being overweight or obese is clinically important in
T2DM because it can exacerbate metabolic abnormali-
ties, leading to further decreases in glycemic control
and worsening of diabetes symptoms [10,11]. In fact,
lifestyle interventions to promote weight loss are gen-
erally considered ﬁrst-line therapy for T2DM and
should be included as part of diabetes management for
all patients [12].
Despite the need for weight loss in T2DM, weight
gain is a common side effect of many therapies for
T2DM and presents a challenge to clinicians because
patients with T2DM are generally overweight before
starting any type of antidiabetic medication [11,13].
Upon initiation of therapy, the average amount of
weight gain seen per patient varies among antidiabetic
agents. Weight gain with various insulins can range
from approximately 2 to 4 kg per patient, and is likely
proportional to the correction of glycemia [12]. While
metformin generally leads to no change in body
weight, and agents, such as exenatide, may lead to a
reduction in body weight [12,14–18].
Because weight gain is common among most thera-
pies to treat T2DM, when examining the value of drug
therapies it should be important to assess not only the
potential impact of weight gain on clinical outcomes,
but also the potential impact on patient HRQOL, pref-
erences, and utility. This review was undertaken to
evaluate the availability of data in the published
medical literature assessing the impact of body weight
on utility scores and to determine what impact, if any,
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different methodologies for eliciting utility scores may
have on the resulting utility values. Speciﬁc research
questions included:
• What is the directional relationship between
weight change and utility in individuals with or
without type 2 diabetes?
• What is the magnitude of utility change based on
body weight or BMI in patients with or without
type 2 diabetes?
• What are the similarities and differences among
published utility/disutility values associated with
change in body weight?
Methods
A review of the medical literature from 1996 to present
was conducted using MEDLINE, EMBASE, and Psy-
cINFO to identify studies assessing the impact of body
weight on patient utility. Additionally, abstracts from
relevant professional conferences from January 2004
to May 2006 were searched. Keywords and MeSH
terms included: body weight, body-mass index, BMI,
obesity, diabetes, weight reduction, weight loss, quality
of life, utilities, health status, health state prefe-
rences, cost-utility, quality-adjusted life-year, cost-
effectiveness, rimonabant, orlistat, sibutramine, and all
combinations of these terms. References listed in rel-
evant journal articles were also reviewed. Because the
focus was to evaluate utility scores based on a change
in body weight for utilization of antidiabetic therapies,
utility scores associated with speciﬁc surgical interven-
tions or dietary modiﬁcation programs were excluded
from this review. The literature search was current as
of May 2006.
Studies were included in the review if they were:
• conducted in adults (18 years old or less);
• written in English;
• used a validated rating scale or methodology (e.g.,
standard gamble [SG] or time trade-off [TTO]) to
elicit utility scores; and
• provided a clear deﬁnition of utility score anchors
of 0 to 1.
Studies were excluded from the review if they:
• did not present utility scores or change in utility
scores by BMI or body weight;
• focused on utility scores obtained from evalua-
tions of surgical treatments or dietary modiﬁca-
tion for obesity rather than pharmacological
treatments;
• were conducted in children (less than 18 years
old);
• only included utility estimates derived from
another study; and
• did not provide a clear methodology for eliciting
utility scores.
Results
General Findings
Sixty articles ﬁtting the search criteria above were
identiﬁed. Of these, 42 were eliminated because they
did not provide speciﬁc data on patient utility, were
conducted during the evaluation of a surgical weight
loss procedure, or did not use validated instruments to
evaluate patient utility. Eighteen articles meeting the
inclusion criteria described above were identiﬁed and
presented either: 1) utility values by BMI or body
weight, or 2) changes in utility scores or quality-
adjusted life-years (QALYs) based on unit changes in
BMI or body weight. In one case, more than one article
was published based on the ﬁndings from one study.
Bagust and Beale [19] present data for the entire Cost
of Diabetes in Europe—Type 2 (CODE-2) study popu-
lation in ﬁve European countries, while Redekop et al.
[20] present a subset of CODE-2 data from The Neth-
erlands. These articles present different aspects of
utility data and are included as separate entries in this
review.
Table 1 presents the articles included in this review
alphabetically by author and grouped by study popu-
lation (e.g., diabetics, general population, hospital
inpatients). The main differences between studies
included variations in sample size, study population,
country included in the study, methods used to elicit
utility scores, and main study outcomes (e.g., utility
score by BMI category or change in utility score asso-
ciated with a change in BMI measurement).
Four articles reported the impact of weight loss on
utility scores and, as expected, utility increased as body
weight decreased [22,24,34,35]. Seven papers reported
studies conducted in patients with diabetes or had a
subset of patients with diabetes from which utility
values speciﬁc to diabetic patients could be derived
[19–25]. Two articles were based on obese or over-
weight patients, or included a subset of obese or over-
weight individuals [22,34]. Five articles included
hospital inpatients or outpatients [23,25–27,35] and
six studies were conducted in individuals from the
general population of various countries [28–31,33,36].
Table 2 shows studies whose main outcomes present
utility scores by BMI level or body weight. Table 3
includes studies in which the main outcome is to
present the change in utility score associated with spe-
ciﬁc increases or decreases in BMI or body weight.
Regardless of the study population or methodology
used to elicit utility scores, all studies reviewed gener-
ally found that as body weight increased, patient utility
decreased. In two studies [22,25], an increase in utility
was observed for some higher BMI subgroups rather
than the expected decrease in utility. Reasons for these
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unexpected results were not clearly explained by the
study authors. Overall, however, the structure of the
data for studies included in this review indicated an
inverse relationship between obesity or higher BMI
and health utility.
Main Differences and Limitations of Studies Evaluating
BodyWeight and Utility
There are several limitations in the studies evaluating
the impact of body weight on patient utility from the
medical literature. In addition to general study limita-
tions, such as small sample sizes or differences in BMI
thresholds, there are several issues that may compro-
mise the use of current utility estimates from the pub-
lished literature in CUAs of therapies for T2DM.
Caution should be used when comparing the utility
values from each study because the studies identiﬁed
differ in four main ways, including differences in: 1)
study population; 2) methods for eliciting utility
scores; 3) expression of study outcomes; and 4) under-
lying assumptions used in determining the change in
utility scores seen with a change in body weight or
BMI (Table 1).
Study population. The impact of body weight or BMI
on patient utility was evaluated using several different
study populations, including individuals with diabetes,
obese individuals, hospital inpatients or outpatients,
general practice patients, and the general population.
Studies were conducted in Australia, Europe, and
North America (Table 1).
In general, utility scores obtained from patients
with diabetes were lower across all levels of BMI than
scores obtained from the general population (Table 2).
Utility scores for individuals of normal weight without
diabetes (BMI of less than 25 kg/m2) ranged from a
low of 0.71 [28] to a high of 0.93 [33]. For obese
individuals without diabetes, utility scores ranged
from a low of 0.60 [31] to a high of 0.91 [33]. For
patients with diabetes who are of normal weight (BMI
of less than 25 kg/m2), utility scores ranged from 0.57
[25] to 0.77 [20]. Utility scores decreased for individu-
Table 1 Comparison of studies evaluating the impact of body weight on patient utility
Source n Study population Country Utility methods
Main outcome
examined by study
[19] 4,641 T2DM Belgium, Italy,The
Netherlands,
Spain, Sweden
TTO,VAS Change in utility score with a change
in BMI
[21] 2,048 T1DM or T2DM US QWB-SA Utility score by BMI category, gender,
and diabetes therapy
[22] 402 Obese patients with and
without hyperglycemia
US TTO,VAS Change in utility score with a decrease in
BMI Utility score by BMI category
[23] 27,249
(2,575 with
diabetes)
Hospital inpatients and
outpatients
UK EQ-5D index Change in utility score with a change in
BMI and utility score by BMI category
[24] 129 T2DM Scotland and
England
VAS, SG Change in utility score with a 3% or 5%
gain or loss of body weight
[25] 14,775 Hospital inpatients and
outpatients with a subset of
T1DM or T2DM patients
UK EQ-5D index Utility score by BMI category
[20] 1,348 T2DM The Netherlands EQ-5D Index and VAS Utility score by BMI category
[26] 18,223 Hospital inpatients and
outpatients
UK EQ-5D Change in utility score with a change in BMI
[27] 13,152 Hospital inpatients and
outpatients
UK EQ-5D, SF-6D Change in utility score with a change in BMI
[28] 1,326 General population US QWB Utility score by BMI category
[29] 13,646 General population US SF-12, EQ-5D Index,
EQ-5DVAS
Change in utility score by BMI category
[30] 12,661 General population Australia SF-36, SF-6D Change in utility score with a change in BMI
and utility score by BMI category
[31] 31,397 General population US HALex Utility score by BMI category and gender
[32] 1,865 General practice patients
45 years old
UK EQ-5D Index, EQ-5D
VAS, SF-6D
Utility score by BMI category
[33] 38,151 General population Canada HUI-3 Utility score by BMI category
[34] —* Individuals with a BMI
between 27 and 40 kg/m2
—* SF-36 Change in utility score by kg of weight lost
[35] 365 Hospital-based primary
care patients
US SG,TTO Utility score at current weight, a BMI =
25 kg/m2 or with a 5%, 10%, 20% weight
loss
[36] — General population UK EQ-5D Index Utility score by BMI category and gender
*This study is a cost-utility analysis of sibutramine and uses quality of life estimates from four clinical trials [37] (n = 854) and from the German Sibutramine Adiposity Therapy
Trial, which is unpublished.The sample size for the German trial was not provided.The quality of life estimates were transformed into utility values byWarren et al. [34] for use
in a UK-speciﬁc cost-utility analysis.
BMI, body-mass index; CODE-2, cost of diabetes type 2 in Europe; EQ-5D, EuroQoL 5-D instrument; QWB, Quality ofWell-Being Index; QWB-SA, Quality ofWell-Being Index
Self-Administered; SF-36, Medical Outcomes Study Short-Form 36; SF-12, Medical Outcomes Study Short-Form 12; SF-6D, a summary preference-based health measure derived
from the SF-36; SG, standard gamble;T1DM, type 1 diabetes mellitus;T2DM, type 2 diabetes mellitus;TTO, time trade-off;VAS, visual analog scale.
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als with diabetes considered obese (BMI of 30 kg/m2 or
more) and ranged from a low of 0.33 [25] to a high of
0.70 [20].
When evaluating utility, the choice of study popu-
lation is particularly important because the impact of a
change in weight varies across different study popula-
tions. For example, weight management is a corner-
stone of diabetes management and patients with
T2DM who are overweight or obese are likely to have
been told to lose weight as part of the therapeutic
approach to managing their disease. Thus, a change in
body weight may have more impact in these patients
and could have a greater effect on utility compared
with the general population. Although statistical
analyses were not conducted, the ﬁndings from this
review are consistent with this hypothesis, in that
Table 2 Utility values by body-mass index or body weight from the published medical literature
Source Method(s)
Study
population Main outcome
[22] TTO,VAS Overweight and obese
patients with and
without hyperglycemia
TTO VAS
Overweight (25–29.9 kg/m2) 0.88 0.77
Obese I (30.0–34.9 kg/m2) 0.85 0.74
Obese II (35–39.9 kg/m2) 0.79 0.67
Obese III (40 kg/m2) 0.81 0.69
[23]* EQ-5D index Hospital inpatients
and outpatients
Normal weight (<25 kg/m2) 0.73
Overweight (25–29.9 kg/m2) 0.69
Obese (30–39.9 kg/m2) 0.62
Extremely obese (40 kg/m2) 0.47
T2DM subset Normal weight (<25 kg/m2) 0.62
Overweight (25–29.9 kg/m2) 0.59
Obese (30–39.9 kg/m2) 0.51
Extremely obese (40 kg/m2) 0.40
[25] EQ-5D Index Hospital inpatients
and outpatients with
a subset of T1DM or
T2DM patients
BMI No diabetes T1DM T2DM
22 0.73 0.79 0.60
24 0.72 0.78 0.57
26 0.69 0.82 0.53
28 0.67 0.75 0.58
30 0.65 0.58 0.55
32 0.60 0.48 0.55
34 0.56 0.58 0.47
36 0.59 0.33 0.44
[20] EQ-5D index
and VAS
T2DM All T2DM patients: 0.74 (Index); 0.68 (VAS)
Obese: 0.70 (Index); 0.66 (VAS)
Not obese: 0.77 (Index); 0.69 (VAS)
[28] QWB General population Underweight (<20 kg/m2) 0.698
Normal (20–24.9 kg/m2) 0.709
Overweight (25–29.9 kg/m2) 0.695
Obese (30.0 kg/m2) 0.663
[31] HALex General population Men Women
Normal (18.5–24.9 kg/m2) 0.86 0.86
Overweight (25–29.9 kg/m2) 0.87 0.82
Obese class 1 (30–34.9 kg/m2) 0.83 0.79
Obese class 2 (35–39.9 kg/m2) 0.79 0.75
Seriously obese (40–49.9 kg/m2) 0.76 0.71
Superobese (50–90 kg/m2) 0.68 0.60
[32] EQ-5D index,
EQ-5D,VAS,
SF-6D
General practice
patients 45 years old
Index EQ-VAS SF-6D
Normal 0.80 77.8 0.78
Preobese 0.78 75.4 0.77
Obese I 0.70 69.8 0.72
Obese II 0.68 66.8 0.67
Obese III 0.62 58.5 0.67
[33] HUI-3 General population Normal (19–24.9 kg/m2) 0.93
Overweight (25–29.9 kg/m2) 0.93
Obese (30.0–34.9 kg/m2) 0.91
Morbidly obese (35 kg/m2) 0.89
[36] EQ-5D Index General population Men Women
Normal (18.5–24.9 kg/m2) 0.877 0.879
Overweight (25–29.9 kg/m2) 0.894 0.871
Obese (30 kg/m2) 0.858 0.812
*Data are estimates obtained from a graph presented in the article.Actual values were not presented.
BMI, body-mass index; EQ-5D, EuroQoL 5-D instrument; HALex, Health and Activities Limitation Index; HUI-3, Health Utilities Index—Version 3; QWB, Quality of Well-Being
Index;QWB-SA,Quality ofWell-Being Index Self-Administered; SF-36,Medical Outcomes Study Short-Form 36; SF-12,Medical Outcomes Study Short-Form 12; SF-6D, a summary
preference-based health measure derived from the SF-36; SG, standard gamble;T1DM, type 1 diabetes mellitus;T2DM, type 2 diabetes mellitus;TTO, time trade-off;VAS, visual
analog scale.
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patients with diabetes had slightly larger changes in
utility scores with a one unit change in BMI compared
with individuals who did not have diabetes [22,23]
(Table 3).
Methodologies to elicit utility scores. Of the 18
articles evaluating the impact of body weight on
patient utility, seven used more than one methodology
to elicit utility scores. Multiattribute health status clas-
siﬁcation systems, such as the EQ-5D, were the most
frequently used method to elicit utility scores in studies
evaluating the impact of body weight on patient utility
(Fig. 1). Only two studies used SG and three studies
used TTO to elicit utility scores, which are considered
the gold standard methods for obtaining utility scores.
As seen in other studies [38–40], utility scores obtained
using SG techniques were generally higher than those
using other methods.
Wee et al. [35] used an SG approach to evaluate the
impact of a 5%, 10%, or 20% weight loss in patients
in a primary care setting in the United States. Utility
scores increased as the magnitude of weight loss
increased, regardless of baseline weight. Similar
improvements in utility were seen in patients with type
2 diabetes in the United Kingdom [24]. When type 2
diabetes patients evaluated a 5% weight loss, utility
increased from 0.89 to 0.92 (a 0.03 increase in utility,
which is similar to the ﬁndings of Wee et al. [35]). The
study by Secnik et al. was the only article to evaluate
the impact of a speciﬁc amount of weight gain on
utility. When patients with type 2 diabetes evaluated a
5% weight gain, utility decreased from 0.89 to 0.83
[24].
Generally, existing studies have not examined the
utility or disutility of small differences in body weight
from the patient’s perspective. Many published
studies have found that individuals with a higher
BMI generally report lower utility compared with
individuals with lower BMI levels [20,23,30–32].
Other than the studies by Secnik et al. [24] and Wee
et al. [35], however, no studies have directly assessed
patients’ preferences, and the associated utilities or
disutilities, for a weight higher or lower than his or
her own.
Expression of study outcomes. Published studies
mainly used multiattribute health status classiﬁcation
systems or visual analog scales (VAS) to evaluate utility
values in a population and then stratiﬁed by BMI.
These studies present utility values by BMI and
attribute the difference in utility scores to differences in
BMI oftentimes controlling for observed factors using
regression analyses. Twelve studies presented the
change in utility associated with a speciﬁc change in
body weight, BMI, or obesity classiﬁcation (e.g., obese
I, obese III, obese III) (Table 3). The change in utility
ranged from a low of 0.0061 to a high of 0.29 per one
unit change in BMI. Both the highest and lowest
changes in utility values, however, came from the same
study by Bagust and Beale [19] and showed the wide
variation in utility changes obtained using TTO versus
VAS.
Of the studies presenting a change in utility score
associated with a change in BMI in individuals without
diabetes, four present the utility change attributable to
a one unit change in BMI [22,23,27,30] and one pre-
sents the utility change per kilogram of weight lost
[34]. There is a large variation in the utility change
seen in studies conducted in individuals without dia-
betes. With a one unit increase in BMI, utility scores
decreased by a low of 0.0024 obtained using the SF-36
[30] to a high of 0.0168 obtained using the EQ-5D
[27]. Hakim et al. [22] found that in obese patients, for
each unit decrease in BMI, utility increased by
approximately 0.02 via TTO or VAS.
These studies do not speciﬁcally evaluate how a
change in weight will affect patients, but rather they
evaluate the HRQOL of patients at various BMI levels.
This is, however, not the same as evaluating the impact
of a speciﬁc amount of weight change. Only two
studies speciﬁcally evaluated the change in utility
scores by asking patients to evaluate the impact of
speciﬁc amounts of weight gain or loss [24,35].
Underlying assumptions. Most studies presented
utility scores stratiﬁed by BMI categories and used
regression analyses to attribute the difference in utility
scores to differences in weight while controlling for
other factors. These studies generally assumed that a
constant change in utility occurs with a one unit
change in BMI. Two recent studies, however, demon-
strate that the magnitude of changes in utility scores
may vary depending on 1) whether a patient is valuing
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Figure 1 Eighteen articles evaluated the impact of body weight on
patient utility. Several articles used more than one methodology to elicit
utility scores.Multiattribute health status classiﬁcation systems, such as the
EQ-5D, were the most frequently used method to elicit utility scores in
studies evaluating the impact of body weight on patient utility. MA, mul-
tiattribute health status classiﬁcation system; SG, standard gamble; TTO,
time trade-off;VAS, visual analog scale.
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weight loss or gain; 2) whether a smaller or larger
change in body weight is being evaluated; and 3) base-
line BMI [24,26].
In studies that present the change in utility score
associated with a change in BMI or body weight, it is
difﬁcult to tell whether the relative change would be
the same if a patient lost weight versus gained weight.
Only one study [24] evaluated equivalent magnitudes
of weight loss and weight gain within a study popula-
tion. Secnik et al. [24] evaluated the impact of a 3%
and 5% weight loss and a 3% and 5% weight gain
within the same population of patients with T2DM.
When patients evaluated the impact of weight gain, the
decreases in utility scores from baseline (patient’s
current weight) were larger than the increases in utility
scores from baseline seen when patients evaluated
weight loss (Table 3).
Conclusions
Although several studies have evaluated the impact of
being overweight or obese on HRQOL, the impact of
changes in body weight on patient utility is less clear.
A thorough review of published estimates of utility
related to obesity was conducted by Dixon et al. [27]
and provided insight into the importance of including
the impact of obesity on HRQOL in economic analy-
ses fully to evaluate therapeutic interventions. The
current study adds to the existing literature in several
important ways: 1) this review includes several recent
publications evaluating the impact of changes in body
weight on patient utility; 2) the impacts of both
weight gain and weight loss are included in this
review; and 3) studies conducted in individuals with
and without diabetes are included, which is particu-
larly important because obesity plays a key role in
the development and progression of diabetes. Addi-
tionally, because antidiabetic agents have different
effects on body weight, it is important to quantify the
impact of different changes in weight on patient pref-
erences fully to understand the value of each therapy.
There were several limitations to this review of the
medical literature. First, the literature search was
limited to articles published in English, which could
potentially be a source of bias and limits the gener-
alizability of the ﬁndings of this review. Second, the
literature search excluded utility values obtained
from studies evaluating surgical procedures for
weight loss; however, utility values obtained from
studies evaluating pharmaceutical therapies for
weight loss were included. Because surgical proce-
dures may lead to a greater magnitude of weight loss
compared with pharmaceutical therapies, the impact
on patient utility may be much larger and may not be
appropriate for inclusion in CUAs to evaluate the
value of pharmaceutical therapies for conditions,
such as T2DM. Third, to allow for comparison
between studies, all of the studies included in this
review evaluated the change in body weight using
BMI levels or categories or magnitude of weight lost
or gained. Studies using other clinically relevant mea-
sures of weight loss (i.e., waist to chest ratio) were
not included in this literature review. To our knowl-
edge, however, the majority of studies evaluating the
impact of body weight on patient utility were con-
ducted using BMI or body weight. Other measures of
weight loss have not been used to evaluate the impact
of body weight on patient utility.
This literature review has identiﬁed several recent
studies describing the impact of body weight, BMI,
and obesity on patient utility scores in patients with
and without diabetes. Although utility scores varied by
study, regardless of the study population or methodol-
ogy used to elicit utility scores, each study found an
inverse relationship between body weight and patient
utility. This ﬁnding is consistent with that of Dixon
et al. [27], who evaluated the relationship between
patient utility and obesity.
Many studies evaluating the impact of body weight
on utility have primarily used a multiattribute ap-
proach with generic questionnaires or a VAS. The
majority of published studies present utility scores by
BMI levels and do not actually ask the individual to
evaluate how a change in body weight will affect his or
her preference for different magnitudes of weight loss.
Additionally, some published utility studies assume
that the impact of weight on utility scores is a linear
function by assuming that the change in utility score is
the same for any one unit change in BMI, regardless of
the starting or ending BMI. Additional research fully
to evaluate this assumption is needed.
When conducting CUAs for antidiabetic agents, the
impact of a change in weight may play an important
role in determining patient preferences for alternative
therapies when estimating cost per QALY. Consistent
with conclusions from Tucker et al. [41], there is a lack
of suitable utility estimates for economic modeling of
antidiabetic agents that account for the effects of
changes in BMI on health state preferences. Various
utility values associated with body weight using differ-
ent methodologies have been published. Careful con-
sideration should be given to determine the most
appropriate utility values to use in CUAs of T2DM
therapies.
Because there is wide variation in the impact of BMI
on utility values, care should be taken to choose utility
values for the base case of a CUA that most closely
reﬂect the potential study population and drug
attributes being evaluated. Conducting sensitivity
analyses by using estimates from different studies in
the published literature is strongly recommended.
Source of ﬁnancial support: Funding for this study was pro-
vided by Eli Lilly and Company.
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Supplementary material for this article can be found at:
http://www.ispor.org/valueinhealth_index.asp.
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